Sorafenib with or without everolimus in patients with unresectable hepatocellular carcinoma (HCC): A randomized multicenter phase II trial (SAKK 77/08 and SASL 29).
Dieter Koeberle
Consultant or Advisory Role - Amgen; Bayer Schering Pharma; Merck Serono; Sanofi
Other Remuneration - Bayer Schering Pharma
Jean-Francois Dufour
Consultant or Advisory Role - Bayer Schering Pharma; Novartis
Honoraria - Bayer Schering Pharma; Novartis
Gyula Demeter
No relevant relationships to disclose
Panagiotis Samaras
No relevant relationships to disclose
Piercarlo Saletti
No relevant relationships to disclose
Qiyu Li
No relevant relationships to disclose
Arnaud Roth
Consultant or Advisory Role - Bayer Schering Pharma
Other Remuneration - Bayer Schering Pharma
Daniel Horber
No relevant relationships to disclose
Michael Buehlmann
No relevant relationships to disclose
Anna Dorothea Wagner
No relevant relationships to disclose
Michael Montemurro
No relevant relationships to disclose
Gabor Lakatos
No relevant relationships to disclose
Karin Ribi
No relevant relationships to disclose
Jonas Feilchenfeld
Honoraria - Bayer Schering Pharma
Research Funding - Novartis
Markus Peck-Radosavljevic
Consultant or Advisory Role - Bayer Schering Pharma; Novartis
Honoraria - Bayer Schering Pharma; Novartis
Research Funding - Bayer Schering Pharma
Daniel Rauch
No relevant relationships to disclose
Ivana Cvijetic
No relevant relationships to disclose
Britta Tschanz
No relevant relationships to disclose
Gyorgy Bodoky
Consultant or Advisory Role - Bayer Schering Pharma; Lilly; Roche
Honoraria - Amgen; Bayer Schering Pharma